Total Synthesis of [14C]-Labelled Homoharringtonine

Autor:	Linli He, Melanie Marguerit, Roger P. Bakale, Shawn P. Allwein, Jason Rossi, James J. Reif, Yi Wang, Renee C. Roemmele, Gill Little
Rok vydání:	2015
Předmět:	Food and drug administration chemistry.chemical_compound Adult patients Chemistry Balance study Homoharringtonine Organic Chemistry Omacetaxine mepesuccinate Total synthesis Myeloid leukemia Good manufacturing practice Physical and Theoretical Chemistry Pharmacology
Zdroj:	European Journal of Organic Chemistry. 2015:8003-8010
ISSN:	1434-193X
DOI:	10.1002/ejoc.201500906
Popis:	A total synthesis of enantiomerically pure [14C]-labelled (–)-homoharringtonine in 17 steps is reported. This synthetic process enabled the production of Good Manufacturing Practice (GMP) compliant (–)-[14C]homoharringtonine that was used in a human mass balance study that was a post-approval commitment to the U.S. Food and Drug Administration. (–)-Homoharringtonine, also called omacetaxine mepesuccinate, is approved to treat adult patients with chronic myeloid leukemia (CML), a blood and bone marrow disease. In November 2012, the product was commercialised as Synribo® in the U.S., marketed by Teva Pharmaceuticals.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9ae56591f1fc2c09acd4501f446347e8 https://doi.org/10.1002/ejoc.201500906 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.